US 9,808,627 B2
Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy
Bradford Evan Gliner, Sammamish, WA (US); Allen Wyler, Seattle, WA (US); Brad Fowler, Woodinville, WA (US); W. Douglas Sheffield, Seatac, WA (US); Richard Kuntz, Lakebay, WA (US); Kent Leyde, Redmond, WA (US); and Leif R. Sloan, Seattle, WA (US)
Assigned to ADVANCED NEUROMODULATION SYSTEMS, INC., Plano, TX (US)
Filed by Advanced Neuromodulation Systems, Inc., Plano, TX (US)
Filed on Nov. 16, 2015, as Appl. No. 14/942,800.
Application 12/327,711 is a division of application No. 11/182,713, filed on Jul. 15, 2005, granted, now 7,483,747, issued on Jan. 27, 2009.
Application 14/942,800 is a continuation of application No. 14/101,189, filed on Dec. 9, 2013, granted, now 9,186,510, issued on Nov. 17, 2015.
Application 14/101,189 is a continuation of application No. 13/179,133, filed on Jul. 8, 2011, granted, now 8,606,361, issued on Dec. 10, 2013.
Application 13/179,133 is a continuation of application No. 12/327,711, filed on Dec. 3, 2008, granted, now 7,983,762, issued on Jul. 19, 2011.
Claims priority of provisional application 60/588,406, filed on Jul. 15, 2004.
Prior Publication US 2016/0067496 A1, Mar. 10, 2016
Int. Cl. A61N 1/36 (2006.01); A61N 1/05 (2006.01); A61N 1/372 (2006.01)
CPC A61N 1/36135 (2013.01) [A61N 1/3606 (2013.01); A61N 1/36146 (2013.01); A61N 1/0531 (2013.01); A61N 1/0534 (2013.01); A61N 1/36064 (2013.01); A61N 1/36067 (2013.01); A61N 1/36082 (2013.01); A61N 1/36103 (2013.01); A61N 1/37252 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A method of treating Parkinson's disease (PD) in a patient, the method comprising:
receiving one or more signals from a patient-controller input device that is indicative of self-administration of Levodopa or other dopamine agonist;
in response to the receiving, communicating one or more signals by the patient-controller input device to an implantable pulse generator to initiate a pre-defined stimulation protocol to accommodate for metabolization of the administered Levodopa or dopamine agonist, wherein the pre-defined stimulation protocol comprises:
(a) applying a first stimulation program, the first stimulation program including stimulation parameters selected to, provide an optimal stimulation therapy after a drug-onset time of the administered Levodopa or dopamine agonist;
(b) applying a second stimulation program, the second stimulation program including stimulation parameters selected to provide an optimal stimulation therapy for a drug half-life of the administered Levodopa or dopamine agonist; and
(C) applying a third stimulation program, the third stimulation program including stimulation parameters selected to provide an optimal stimulation therapy for drug level substantially below a level expected for the drug half-life of the administered Levodopa or dopamine agonist;
wherein the applying, the first, second, and third stimulation programs occurs automatically by the implantable pulse generator implanted in the patient in response to the implantable pulse generator receiving the one or more signals from the patient-controller input device, and wherein operation of the implantable pulse generator according to the second stimulation program provides reduced power consumption compared to operation of the implantable pulse generator according to the third stimulation program.